COMPUGROUP MEDICAL SOCIETAS EUROPAEA
DGAP Post-admission Duties announcement: CompuGroup Medical SE / Share Buyback CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 14th Interim Announcement, concurrently Completion Announcement CompuGroup Medical SE / Share Buyback Koblenz, March 20, 2019 CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 14th Interim Announcement, concurrently Completion Announcement In the period from March 18, 2019, up to and including March 19, 2019, CompuGroup Medical SE has bought back a total of 12,173 shares of CompuGroup Medical SE within the framework of the share buyback program. In the announcement of December 14, 2018, pursuant to Art. 2 para. 1 of the Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR), it was communicated that the repurchase of treasury shares would commence on December 17, 2018. The share buyback, in the framework of which until at the latest April 30, 2019 up to 500,000 treasury shares of the Company should be repurchased exclusively via the stock exchange in electronic trading through the Frankfurt Stock Exchange (Xetra), corresponding to a portion of the current nominal share capital of approximately 0.94%, yet subject to an overall purchase volume limit of EUR 20,000,000.00 (excluding ancillary costs of purchase), was completed on March 19, 2019. The overall volume of the shares bought back daily in the period from March 18, 2019, up to and including March 19, 2019, and the daily volume-weighted average stock market prices of the shares are as follows:
The total number of shares which have been bought back by CompuGroup Medical SE in the period from December 17, 2018, up to and including March 19, 2019 within the framework of the share buyback program amounts to 426,153 no-par value shares. This corresponds to a portion of the current nominal share capital of CompuGroup Medical SE of approximately 0.80%. The average purchase price (volume-weighted average stock market price in EUR, excluding ancillary costs of purchase, rounded to four places according to commercial practice) amounted to EUR 46.9314 per share. In aggregate, shares were bought back in an overall purchase volume of EUR 19,999,962.61 (excluding ancillary costs of purchase). Further information pursuant to Art. 5 para. 1 lit. b) and para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 para. 2 and para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available online under https://www.cgm.com/sbb. The purchase of the shares of CompuGroup Medical SE was carried out by a bank assigned by CompuGroup Medical SE and exclusively via the Frankfurt Stock Exchange (Xetra trading). Koblenz, March 20, 2019 The Management Board CompuGroup Medical SE
20.03.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | CompuGroup Medical SE |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Internet: | www.cgm.com |
| End of News | DGAP News Service |
789705 20.03.2019
